Home › Compare › CRXTQ vs RYLD

CRXTQ vs RYLD: Dividend Comparison 2026

CRXTQ yields 142857.14% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRXTQ wins by $1.703105290929614e+28M in total portfolio value
10 years
CRXTQ
CRXTQ
● Live price
142857.14%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.703105290929614e+28M
Annual income
$17,007,633,297,048,937,000,000,000,000,000,000.00
Full CRXTQ calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — CRXTQ vs RYLD

📍 CRXTQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRXTQRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRXTQ + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CRXTQ pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRXTQ
Annual income on $10K today (after 15% tax)
$12,142,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,456,488,302,491,595,000,000,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, CRXTQ beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRXTQ + RYLD for your $10,000?

CRXTQ: 50%RYLD: 50%
100% RYLD50/50100% CRXTQ
Portfolio after 10yr
$8.51552645464807e+27M
Annual income
$8,503,816,648,524,468,000,000,000,000,000,000.00/yr
Blended yield
99.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CRXTQ right now

CRXTQ
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRXTQ buys
0
RYLD buys
0
No recent congressional trades found for CRXTQ or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRXTQRYLD
Forward yield142857.14% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.703105290929614e+28M$44.5K ✓
Annual income after 10y$17,007,633,297,048,937,000,000,000,000,000,000.00 ✓$2,587.35
Total dividends collected$1.70295189426983e+28M$18.8K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CRXTQ vs RYLD ($10,000, DRIP)

YearCRXTQ PortfolioCRXTQ Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$14,296,414$14,285,714.29$11,914$1,213.65+$14.28M → CRXTQ
2$19,102,632,658$19,087,335,494.95$14,099$1,351.30+$19102.62M → CRXTQ
3$23,856,124,353,624$23,835,684,536,679.88$16,580$1,494.55+$23856124.34M → CRXTQ
4$27,845,102,711,212,050$27,819,576,658,153,670.00$19,384$1,642.61+$27845102711.19M → CRXTQ
5$30,376,787,884,694,190,000$30,346,993,624,793,194,000.00$22,535$1,794.70+$30376787884694.16M → CRXTQ
6$30,972,831,647,170,750,000,000$30,940,328,484,134,132,000,000.00$26,063$1,950.00+$30972831647170752.00M → CRXTQ
7$29,516,720,240,819,920,000,000,000$29,483,579,310,957,454,000,000,000.00$29,995$2,107.69+$29516720240819920896.00M → CRXTQ
8$26,290,911,335,300,946,000,000,000,000$26,259,328,444,643,270,000,000,000,000.00$34,361$2,266.99+$2.6290911335300947e+22M → CRXTQ
9$21,887,488,081,496,375,000,000,000,000,000$21,859,356,806,367,600,000,000,000,000,000.00$39,194$2,427.12+$2.1887488081496375e+25M → CRXTQ
10$17,031,052,909,296,140,000,000,000,000,000,000$17,007,633,297,048,937,000,000,000,000,000,000.00$44,525$2,587.35+$1.703105290929614e+28M → CRXTQ

CRXTQ vs RYLD: Complete Analysis 2026

CRXTQ — Stock

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full CRXTQ Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this CRXTQ vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRXTQ vs SCHDCRXTQ vs JEPICRXTQ vs OCRXTQ vs KOCRXTQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.